학술논문
The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry
Document Type
article
Author
Ryusuke Nishikawa; Takao Kato; Takeshi Morimoto; Hidenori Yaku; Yasutaka Inuzuka; Yodo Tamaki; Erika Yamamoto; Neiko Ozasa; Tomohisa Tada; Hiroki Sakamoto; Yuta Seko; Masayuki Shiba; Yusuke Yoshikawa; Yugo Yamashita; Takeshi Kitai; Ryoji Taniguchi; Moritake Iguchi; Kazuya Nagao; Takafumi Kawai; Akihiro Komasa; Yuichi Kawase; Takashi Morinaga; Mamoru Toyofuku; Yutaka Furukawa; Kenji Ando; Kazushige Kadota; Yukihito Sato; Koichiro Kuwahara; Takeshi Kimura; for the KCHF Study Investigators
Source
ESC Heart Failure, Vol 10, Iss 5, Pp 3141-3151 (2023)
Subject
Language
English
ISSN
2055-5822
Abstract
Abstract Aims The use of tolvaptan is increasing in clinical practice in Japan. However, the characteristics of patients who used tolvaptan and the timing of its use in patients with acute heart failure (AHF) are not fully elucidated. Methods and results Among consecutive 4056 patients in the Kyoto Congestive Heart Failure registry, we analysed 3802 patients after excluding patients on dialysis, prior or unknown tolvaptan use at admission, and unknown timing of tolvaptan use, and we divided them into two groups: tolvaptan use (N = 773) and no tolvaptan use (N = 3029). The prevalence of tolvaptan use varied widely from 48.7% to 0% across the participating centres. Factors independently associated with tolvaptan use were diabetes, poor medical adherence, oedema, pleural effusion, hyponatraemia, estimated glomerular filtration rate